demonstrated, in addition to higher weight loss in the group treated with high-dose liraglutide 3.0 mg/day for 32 weeks, significant improvements not only of fasting glucose and HOMA-IR, but also of the post-load glucose measured by OGTT, OGTT-derived insulin sensitivity index (SIOGTT), and corrected the early insulin response to a glucose challenge (IGI/HOMA) compared to placebo [62]
This initial phase typically involves receiving infusions once a week for 4 to 6 weeks
Tirzepatide (Zepbound) Available doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg Starting dose: 2.5 mg weekly Titrated in 2.5 mg increments every 4 weeks Maintenance doses: 5 mg, 10 mg, or 15 mg weekly Higher doses tend to produce greater weight loss, but also increase the likelihood of gastrointestinal side effects and excessive appetite suppression
: L- -L- : ,
This product is not intended to diagnose, treat, cure, or prevent a disease
The weight was dropping